AQST -- Aquestive Therapeutics

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Biotechmaster, Oct 11, 2019.

  1. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
    Market Cap $80 M--Cash $22 Million --FDA Decision on November 30 -- 3 Marketed Drugs including former Blockbuster Suboxone film (opioid dependence) -- 4 Drugs under review by FDA 3 of them with MASSIVE market potential /Undiscovered Low float gem = Potential 10 Bagger here guys ..Check it out this one could run massive ahead of the PDUFA date next month .GL


    Aquestive Therapeutics (AQST)

    Market Cap $80 Million
    Cash: $22 Million
    Price: $3.20


    Presentation
    http://investors.aquestive.com/static-files/01374d64-cc08-4bc1-89e8-b6008edb43a6


    Insider buying
    http://openinsider.com/search?q=aqst



    [​IMG]


    [​IMG]
     
  2. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
    market cap of $83 miillion is a GIFT should be north of $500 million ..

    Upcoming MAJOR Milestones expected during Q4 2019 :

    FDA Decision für Exservan (amyotrophic lateral sclerosis) on November 30

    PoC results (Acromegalie Oral film) during this Q

    NDA submission for Libervant this Q

    NDA resubmission Parkinson drug this Q


    Lagrest Shareholder

    Crestline ...11.5M
    Perceptive ...2.1M
    Monosol ...1.9M
    Schobel ...1.1M
    Kendall (Keith J.) ...729.2K
    Opaleye ...590.0K
    MFS Investment ...473.3K
    BlackRock ...378.3K
    Bratton (Douglas K) ...335.0K
    The Vanguard ...312.1K
     
  3. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
    good numbers ...

    Aquestive backs FY19 revenue $38M-$45M, consensus $42.82M Aquestive Therapeutics announced, in response to Indivior PLC's press release issued earlier today of Indivior's intent to cease production of its authorized generic buprenorphine-naloxone film product, that the company is reaffirming its full year 2019 total revenue guidance. Full year 2019 total revenue is now expected to be at the top end of the company's guidance range of $38M-$45M. Full year 2019 revenue from the company's Suboxone franchise is expected to be at the top end of its guidance range of $29M-$32M. As of October 2019, Suboxone and the authorized generic buprenorphine-naloxone film continue to retain approximately 75% of the market for film treatments of opioid dependence, of which a substantial majority of its retained market share is branded Suboxone.

    Read more at:
    https://thefly.com/landingPageNews.php?id=2975849
     
  4. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
    ralllyyyyyyyy ,, this brutally undervalued stock has good potential to hit $10++ in the coming weeks


    [​IMG]


    [​IMG]
     
  5. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
  6. Biotechmaster

    Biotechmaster Member

    Joined:
    Jun 3, 2016
    Messages:
    293
    Likes Received:
    10
    stock running higher looks like good news on the way
     
  7. shaw520

    shaw520 Member

    Joined:
    Nov 11, 2019
    Messages:
    43
    Likes Received:
    25
    I got in at 6.43,...big buzz going on in the chat forums about the potential of this stock....we shall see.
     
  8. shaw520

    shaw520 Member

    Joined:
    Nov 11, 2019
    Messages:
    43
    Likes Received:
    25
    Nice one month gains,...sitting at 8.74,.. was up to 9 before the close.

    upload_2019-12-2_20-26-45.png
     
  9. shaw520

    shaw520 Member

    Joined:
    Nov 11, 2019
    Messages:
    43
    Likes Received:
    25
    $CLVS tanked hard today,.. thanks to $AQST to help soften the blow.
     

Share This Page